Active clinical trials for "Constipation"

A pilot study to evaluate the safety and efficacy of BLI801 vs. placebo in constipated adults.

MOA-728, an investigational drug, is currently being studied for the relief of constipation associated with postoperative ileus and treatment of opioid induced constipation in patients receiving palliative care. This study will further investigate the IV formulation of MOA-728 comparing PK/PD time points for a 20-minute versus a 4-hour infusion.

The purpose of this study was to evaluate the safety and efficacy of Movicol in the treatment of chronic constipation in children.

The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic constipation. Hypothesis: Prucalopride 2 mg and 4 mg given once daily for 12 weeks is superior to placebo for the treatment of patients with chronic constipation and is well tolerated in those patients.

At least 60% of patients with constipation and dyssynergic defecation (anismus) and between 30-50% of patients with fecal incontinence exhibit impaired rectal sensation. The problem may be improved by biofeedback therapy. Traditionally, biofeedback therapy was performed by using a syringe-assisted technique. Although some respond to this method, many, particularly those with severe rectal hyposensitivity have proved to be refractory. Also, repeated inflation and deflation of a large volume of air, using a hand-held syringe is cumbersome and time consuming. Recently, in pilot observations, the investigators have seen that a barostat-assisted technique of biofeedback therapy was simpler and easier to perform and could possibly be more effective. The investigators' aims are: To perform a randomized controlled study that compares the syringe-assisted sensory conditioning (biofeedback therapy) technique with the barostat assisted sensory conditioning for improving the rectal sensation in patients with rectal hyposensitivity and bowel dysfunction. To investigate the impact of sensory conditioning on psychosocial issues and quality of life. To compare the cost-effectiveness of each therapeutic modality The specific hypotheses that will be tested are; When compared to those who receive syringe-assisted training, patients receiving barostat training will demonstrate: Lower sensory thresholds for rectal perception (first sensation, desire to defecate and urgency) Greater satisfaction with bowel function (VAS Score), stool frequency,consistency & straining. Better learning ability and greater ease of administering this training.

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).

Primary Objective: To evaluate the clinical efficacy of Naturetti (capsules) , considering the following criteria: Evacuation frequency during the treatment and follow-up period Consistency of stools during the treatment and follow-up period Global evaluation, regarding increase in frequency of evacuation and shape of stools. Secondary Objective: Number of days without evacuation Proportion of evacuation with pain Proportion of evacuation with strain Proportion of evacuation with incomplete sensation Proportion of blocked stools Proportion of manual maneuvers to facilitate defecation Proportion of subjects that adhere to the diet recommended Proportion of the patients who have to use rescue medication Level of constipation improvement, according to the patient evaluation To evaluate clinical tolerability of the study medication by the continuous use To evaluate the occurrence of adverse events related to the study drug To identify any drug interaction.

The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week. The frequency of spontaneous bowel movements will be determined from a Bowel Function Patient Diary completed by the enrolled sujbects.

The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function. to demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone